ATS (ATS) Q1 2025 earnings summary

Executive summary

• Achieved second-highest order bookings on record at $817 million (up 18.4% year-over-year), led by life sciences and consumer products.

• Q1 revenues were $694.3 million, down 7.9% year-over-year, mainly due to lower transportation revenues and reduced construction contract activity.

• Backlog ended at $1.88 billion, with life sciences backlog at a record $990 million, up 26% year-over-year.

• Integration of Paxiom completed and pending acquisition of Heidolph Instruments to expand offerings and recurring revenues.

• Strategic focus is shifting toward regulated markets like life sciences and food & beverage, supported by recent acquisitions.

Financial highlights

• Q1 adjusted earnings from operations were $86.2 million (12.4% margin), down 16% year-over-year.

• Adjusted EBITDA was $106.0 million (15.3% margin), down from $119.2 million year-over-year.

• Basic EPS was $0.36 (reported) and $0.50 (adjusted), both down year-over-year.

• Free cash flow was negative $51.3 million, improved from negative $130.8 million a year ago.

• Net debt to adjusted EBITDA ratio at 2.7x, within target range.

Outlook and guidance

• Q2 revenue conversion expected at 33%-36% of order backlog, reflecting early phases of large life sciences programs and delayed transportation orders.

• Margins expected to be negatively impacted in Q2 due to lower transportation revenues; cost mitigation actions underway, including workforce reduction costing $15–$20 million.

• No material change to full-year revenue outlook; life sciences strength expected to offset transportation weakness.

• Effective tax rate expected in the 25%-27% range for fiscal 2025.

• Non-cash working capital anticipated to remain elevated short-term, with improvements expected in the second half of the year.